Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade
This study highlights the high progression risk following ICI discontinuation in advanced MCC, especially among patients with non-CRs or those discontinuing early. While elective discontinuation may be appropriate after durable CRs (response≥1 year), greater caution is warranted in other settings.
Authors
- Allison J Remington
- Candice D. Church (ORCID: https://orcid.org/0000-0003-1582-8292)
- Tomoko Akaike (ORCID: https://orcid.org/0000-0003-4525-6408)
- Kristina Lachance (ORCID: https://orcid.org/0000-0002-2697-268X)
- Marika Bierma
- Song Y. Park (ORCID: https://orcid.org/0000-0003-4366-1821)
- Shailender Bhatia (ORCID: https://orcid.org/0000-0002-3816-2238)
- Coley Doolittle‐Amieva
- Thomas H. Pulliam (ORCID: https://orcid.org/0000-0003-3511-6348)
- Nora A. Alexander (ORCID: https://orcid.org/0000-0003-3011-1353)
- Lauren Zawacki
- Lisa Tachiki (ORCID: https://orcid.org/0000-0001-8057-8029)
- Emily Gong
- Daniel S. Hippe (ORCID: https://orcid.org/0000-0003-2427-4404)
- Nikhil Harikrishnan
- Alex Z. Fu (ORCID: https://orcid.org/0000-0002-4020-6519)
- Paul Nghiem (ORCID: https://orcid.org/0000-0003-2784-963X)
- Lisa C. Zaba (ORCID: https://orcid.org/0000-0001-9036-5465)
- Emily Huynh (ORCID: https://orcid.org/0000-0001-9211-0124)
- Yasman Moshiri
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- University of Washington Applied Physics Laboratory (US)
- Stanford University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2025-012123
- Citations
- 2
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- University of Washington
- Kuni Foundation
- National Cancer Institute